B. Riley Financial Inc., seeking to recover from soured investments and a string of losses, has briefed its staff on a ...

Fintel reports that on January 30, 2025, B. Riley Securities initiated coverage of Foghorn Therapeutics (NasdaqGM:FHTX) with ...

Learn about the latest financial trends and strategies in our comprehensive article written by a financial expert.

B. Riley issued their Q1 2025 earnings estimates for Customers Bancorp in a research note issued to investors on Monday, ...

B. Riley analyst Dave Kang raised the firm’s price target on Viavi (VIAV) to $12 from $10 and keeps a Neutral rating on the shares. The company’s ...

B. Riley Financial Inc. suspended dividends on a pair of its preferred shares, holding off on cash payments to some investors ...

B. Riley analyst Mike Crawford upgraded Redwire (RDW) to Buy from Neutral with a price target of $27, up from $9.50. The firm increased fiscal ...

In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), ...

B. Riley analyst Kyle Bauser raised the firm’s price target on ClearPoint Neuro (CLPT) to $20 from $15 and keeps a Buy rating ...

I have covered B. Riley Financial, Inc. or "B. Riley" (NASDAQ:RILY, NASDAQ:RILYL, NASDAQ:RILYP, NASDAQ:RILYM, NASDAQ:RILYK, NASDAQ:RILYN, NASDAQ:RILYG, NASDAQ:RILYT ...

Research analysts at B. Riley increased their FY2024 earnings estimates for FormFactor in a research note issued on Monday, January 27th. B. Riley analyst C. Ellis now forecasts that the semiconductor ...